Search Results - "Dominguez, A Rueda"

Dynamic Exosome Analysis to Predict Response to the Combination of SABR and Immunotherapy in Oligoprogressive Disease by Martin, J. Zafra, Onieva, J.L., Roman, A., Garrido, M., Oliver, J., Martinez-Galvez, B., Dubbelman, J., Mesas, A., Villatoro, R., Ramos, I., Rueda-Dominguez, A., Perez-Ruiz, E., Benitez, J.C., Medina, J.A., Alba, E., Sett, R. Chicas, Barragan, I.

“…Up to 80% of metastatic patients face resistance to immune checkpoint inhibitors (ICI). Combined SABR and ICI (I-SABR) can unleash antitumor immune cascades to…”
Get full text

Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study by Rueda Domínguez, A., Márquez, A., Gumá, J., Llanos, M., Herrero, J., de las Nieves, M. A., Miramón, J., Alba, E.

“…Background: Chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine and darcarbacine) schedule is the standard treatment for advanced Hodgkin's lymphoma…”
Get full text

Epidemiological characteristics of a Spanish cohort of patients diagnosed with squamous cell carcinoma of head and neck: distribution of risk factors by tumor location by Seijas-Tamayo, R., Fernández-Mateos, J., Adansa Klain, J. C., Mesía, R., Pastor Borgoñón, M., Pérez-Ruiz, E., Vázquez Fernández, S., Salvador Coloma, C., Rueda Domínguez, A., Taberna, M., Martínez-Trufero, J., Bonfill Abella, T., Vázquez Estévez, S., Pollán, M., del Barco Morillo, E., Cruz-Hernández, J. J.

“…Purpose Head and neck cancer is a highly heterogeneous disease comprising a large number of tumors located in the cervicofacial area. This study aimed to…”
Get full text

SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma by Provencio Pulla, M., Alfaro Lizaso, J., de la Cruz Merino, L., Gumá i Padró, J., Quero Blanco, C., Gómez Codina, J., Llanos Muñoz, M., Martinez Banaclocha, N., Rodriguez Abreu, D., Rueda Domínguez, A.

“…Follicular non-Hodgkin’s lymphoma (FL) is a nodal B lymphoid malignancy that originates from the germinal center of a lymph node. FL is the second most…”
Get full text

SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma by Rueda Domínguez, A., Alfaro Lizaso, J., de la Cruz Merino, L., Gumá i Padró, J., Quero Blanco, C., Gómez Codina, J., Llanos Muñoz, M., Martinez Banaclocha, N., Rodriguez Abreu, D., Provencio Pulla, M.

“…Hodgkin lymphoma (HL) is an uncommon B cell lymphoid malignancy representing approximately 10–15 % of all lymphomas. HL is composed of two distinct disease…”
Get full text

Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer by Zafra, Juan, Onieva, Juan Luis, Oliver, Javier, Garrido-Barros, María, González-Hernández, Andrea, Martínez-Gálvez, Beatriz, Román, Alicia, Ordóñez-Marmolejo, Rafael, Pérez-Ruiz, Elisabeth, Benítez, José Carlos, Mesas, Andrés, Vera, Andrés, Chicas-Sett, Rodolfo, Rueda-Domínguez, Antonio, Barragán, Isabel

“…Up to 80% of patients under immune checkpoint inhibitors (ICI) face resistance. In this context, stereotactic ablative radiotherapy (SABR) can induce an immune…”
Get full text

CC‐99282 plus R‐CHOP in patients (pts) with previously untreated aggressive B‐cell lymphoma (a‐BCL): early safety and efficacy results from a phase 1b study by Munoz, J., Hoffmann, M., Westin, J., Vassilakopoulos, T. P., García‐Sancho, A. M., Rueda‐Domínguez, A., Jurczak, W., Kwiatek, M., Bouzani, M., Gkasiamis, A., Patel, A., Boucaud, F., Li, J., Nowakowski, G. S.

Get full text

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA by Hutchings, M., Avigdor, A., Sureda, A., Terol, M. J., Bosch, F., Corradini, P., Larsen, T. Stauffer, Domínguez, A. Rueda, Skarbnik, A., Jørgensen, J., Goldschmidt, N., Gurion, R., Zinzani, P. L., Pinto, A., Cordoba, R., Bottos, A., Huang, Z., Simko, S., Relf, J., Filézac de L’Etang, A., Sellam, G., Gritti, G.

Get full text

Preclinical models in head and neck squamous cell carcinoma by Chaves, Patricia, Garrido, María, Oliver, Javier, Pérez-Ruiz, Elisabeth, Barragan, Isabel, Rueda-Domínguez, Antonio

“…Head and neck cancer is the sixth most frequent cancer type. Drug resistance and toxicity are common challenges of the existing therapies, making the…”
Get full text

1481P Singular immune-related adverse events and efficacy outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer by Jurado García, J.M., Cobo Dols, M., Cantero, A., Gutierrez Calderon, V., Jiménez Gallego, P., Perez Ruiz, E., Berciano Guerrero, M.A., Montesa Pino, A., Ramos Garcia, I., Rueda Dominguez, A.

Get full text

2204P Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit by Guardamagna, M., Gonzalez, B. Villaescusa, Dolores, M.R. María, Gonzalez, E. Zamorano, Garcia, I. Ramos, Ruiz, A. Mesas, Perez, J.M. Trigo, Cantero, A., Calderon, V. Gutierrez, García, J.M. Jurado, Dominguez, A. Rueda, Mongil, R., Arrabal, R., Conejo, E. Alba, Dols, M. Cobo, Montanez, J.C. Benitez

Get full text

187P Relationship between immune profile and immunophenotype in early breast cancer by Bravo, C.M.M., Villatoro, R., Pérez, D., Zarcos, I., Robles, L., Rodrigo, I., Pérez-Ruiz, E., Alcaide, J., Rivas-Ruiz, F., Navarro, V., Robles, M., Galeote, A., Cantizani, P., Quero, C., Dominguez, A. Rueda

Get full text

LENALIDOMIDE PLUS R‐GDP (R2‐GDP) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA. PRELIMINARY RESULTS OF THE R2‐GDP‐GOTEL TRIAL by Cruz‐Merino, L., Martín García‐Sancho, A., Nogales Fernández, E., Carnicero González, F., Ríos Herranz, E., Cruz Vicente, F., Rodríguez García, G., Nicolás García, C., Martínez Benaclocha, N., Gumà Padrò, J., Gómez Codina, J., Salar Silvestre, A., Rodríguez Abreu, D., Quero Blanco, C., Labrador Gómez, J., Guirado Risueño, M., Provencio Pulla, M., Rueda Domínguez, A.

Get full text

Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures by Omotesho, Quadri Ajibola, Escamilla, Alejandro, Pérez-Ruiz, Elisabeth, Frecha, Cecilia A, Rueda-Domínguez, Antonio, Barragán, Isabel

“…Tertiary lymphoid structures (TLS) are ectopic lymphoid aggregates found in sites of chronic inflammation such as tumors and autoimmune diseases. The discovery…”
Get full text

1456P Impact of early palliative care in quality at the end of life in small cell lung cancer patients by Jiménez-García, N., Ronco-Dumas, L., Rivas-Ruiz, F., Quirós-López, R., Flores-Guardabrazo, C., Bravo, C.M.M., Jamal-Ismail Ortiz, Y., Pérez-Ruiz, E., Navarro, V., Carrasco-Zafra, M.I., Gómez, R., Domínguez, J.C., Pérez, D., Zarcos, I., Robles, M., Galeote, A., Cantizani, P., Quero, C., Rueda Dominguez, A., Villatoro, R.

Get full text

910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) by Cohen, E.E., Ferris, R.L., Psyrri, A., Haddad, R., Tahara, M., Bourhis, J., Harrington, K.J., Chang, P.M-H., Lin, J-C., Razaq, M., Teixeira, M.M., Lovey, J., Chamois, J., Rueda Dominguez, A., Hu, C., Dvorkin, M., De Beukelaer, S., Pavlov, D., Thurm, H., Lee, N.

Get full text

Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition by Guardamagna, Mora, Berciano-Guerrero, Miguel-Angel, Villaescusa-González, Beatriz, Perez-Ruiz, Elisabeth, Oliver, Javier, Lavado-Valenzuela, Rocío, Rueda-Dominguez, Antonio, Barragán, Isabel, Queipo-Ortuño, María Isabel

“…Gut microbiome (GM) and its either pro-tumorigenic or anti-tumorigenic role is intriguing and constitutes an evolving landscape in translational oncology. It…”
Get full text

1267P - Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy by Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araújo, Carrasco, F Henao, García-Sancho, A Martín, Carnicero, F., Herranz, E Rios, de la Cruz Vicente, F., Fernández, R., Dominguez, A Rueda, de la Cruz Merino, L.

“…Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T lymphocytes. High levels…”
Get full text

1267PEvolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy by Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araújo, Carrasco, F Henao, García-Sancho, A Martín, Carnicero, F, Herranz, E Rios, de la Cruz Vicente, F, Fernández, R, Dominguez, A Rueda, de la Cruz Merino, L

“…Abstract Background Myeloid derived suppresor cells (MDSC) are a heterogeneous population of immature myeloid cells that inhibits antitumor responses by T…”
Get full text

Evolution of myeloid-derived suppressor cells and objective response rate in relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL) patients after receiving immunotherapy by Cortegana, C Jiménez, Carrión, N Palazón, Fernández, E Nogales, García, M A Nieto, Margalet, V Sánchez, de la Gala, M D C Álamo, de Ilárduya, M Suengas Martínez, Burgos, E Montilla, Fernández, I Araújo, Carrasco, F Henao, García-Sancho, A Martín, Carnicero, F., Herranz, E Rios, de la Cruz Vicente, F., Fernández, R., Dominguez, A Rueda, de la Cruz Merino, L.

Get full text